Ark Therapeutics agrees manufacturing partnership
With unnamed European gene therapy company
Ark Therapeutics Group has signed a master manufacturing services agreement with one of Europe’s leading gene therapy companies. The partnership will initially cover Ark’s supply of manufacturing and development services in respect of the partner’s therapeutic vaccine product.
Financial details of the pact were not disclosed.
David Venables, Ark’s executive director of manufacturing said: ‘We are delighted to announce this substantive partnership, which provides further validation of the strong scientific and technological capabilities available at Ark, and the progress we are making in building our strategy for viral focused contract development and manufacturing services.
‘As well as providing state-of-the-art manufacturing capabilities, Ark is also able to bring our partner the benefit of our own experience in developing adenoviral based medicines.’
